Company Overview and News

MQREIT sees 4.48% traded off-market

2018-08-20 theedgemarkets
KUALA LUMPUR (Aug 20): MRCB-Quill REIT (MQREIT) saw 48 million of its units cross off-market today. This represents 4.48% of the REIT's total 1.07 billion outstanding units.

KLCI seen trending sideways, immediate hurdle at 1,809

2018-08-08 theedgemarkets
KUALA LUMPUR (Aug 9): The FBM KLCI is seen trending sideways today with immediate hurdle at 1,809 in line with the global markets where trade jitters kept sentiment in check.
DKSHY 5209 5162 0151 5123 DKSHF 5908

Gas Malaysia, Axis REIT, Perak Corp, Kelington Group, Zecon, IJM Corp, ECS ICT, DKSH, MQReit and AirAsia

2018-08-08 theedgemarkets
KUALA LUMPUR (Aug 8): Based on corporate announcements and news flow today, stocks in focus tomorrow may include the following: Gas Malaysia Bhd, Axis REIT, Perak Corp Bhd, Kelington Group Bhd, Zecon Bhd, IJM Corp Bhd, ECS ICT Bhd, DKSH Holdings (Malaysia) Bhd, MRCB-Quill REIT and AirAsia Group Bhd.
DKSHY FLY 5209 5162 0151 5123 DKSHF 5908

MQReit 2Q net profit up 6.5% to RM23.49m

2018-08-08 theedgemarkets
KUALA LUMPUR (Aug 8): MRCB-Quill REIT (MQReit)'s net profit for the second quarter ended June 30, 2018 rose 6.5% year-on-year to RM23.49 million from RM22.04 million, underpinned by lower property expenses and total expenditure incurred.

New guideline of allowing REITs to engage in property development a sector catalyst

2018-07-13 theedgemarkets
Real estate investment trust sector Maintain neutral: We maintain “neutral” rating on the real estate investment trust (REIT) sector given the general oversupply situation but this should be offset by the appeal of REITs given the current uncertain equity markets. We leave our assumption of 10-year Malaysian government securities (MGS) yield remaining unchanged at 4.1%, and roll forward our valuation to 2019.

MREITs take a real beating

Downtrend: At yesterday’s close, the fall of MREITs widened considerably year to date with CapitaLand Malaysia Mall Trust (CMMT) seeing a 40.2 decline, diversified Sunway REIT (13.09), PavREIT (9.85), AxisREIT (16.77) and IGB REIT (12.98).
5180 5123

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...